Chemical Structure : NCGC-6782
货号: PC-28690Not For Human Use, Lab Use Only.
NCGC-6782 is a potent and selective LATS1/2 inhibitor with IC50 of 1.3 and 2.0 nM against LATS1 and LATS2 in vitro kinase assays, inhibits Hippo signaling pathway for regenerative application.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
NCGC-6782 is a potent and selective LATS1/2 inhibitor with IC50 of 1.3 and 2.0 nM against LATS1 and LATS2 in vitro kinase assays, inhibits Hippo signaling pathway for regenerative application.
NCGC-6782 exhibits EC50 of 21 nM in cell-based NanoBRET readouts.
NCGC-6782 induced rapid (4 h), dose-dependent YAP1 nuclear translocation and robust transactivation of three bona-fide YAP1 target genes AMOTL2, CTGF, and CYR61 and of YAP1/TEAD-dependent transcriptional reporters.
NCGC-6782 shows>200-fold selectivity against AKT1, and about a 15-fold to 30-fold selectivity against ROCK1/2.
NCGC-6782 induces dose-dependent acceleration of wound closure in Hippo-pathway proficient NCI-H28 cells.
NCGC-6782 exhibits favorable pharmacokinetic (PK) profiles following intraperitoneal (IP), intravenous (IV), or oral (PO) dosing, leading to rapid inhibition of YAP-phosphorylation in murine liver samples.
NCGC-6782 accelerates proliferative regeneration in both cell-based and in vivo wound healing models of full-thickness excisional skin injury, significantly shortening wound-closure time without evidence of systemic toxicity.
| 分子量 | 493.58 | |
| 分子式 | C27H32FN5O3 | |
| 外观性状 | Solid | |
| 储存条件 |
|
|
| Solubility |
10 mM in DMSO |
|
1. Tosto FA, et al. Proc Natl Acad Sci U S A. 2026 Nov 10;123(45):e2602240123.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright